バイオシミラー(バイオ後続品)の世界市場2018-2022

◆英語タイトル:Global Biosimilars Market 2018-2022
◆商品コード:IRTNTR21998
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月6日
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、バイオシミラー(バイオ後続品)の世界市場について調査・分析し、市場概要、市場環境、バイオシミラー(バイオ後続品)市場規模、用途別(腫瘍学・血液学、内分泌学、免疫学、腎臓学)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・バイオシミラー(バイオ後続品)の世界市場概要
・バイオシミラー(バイオ後続品)の世界市場環境
・バイオシミラー(バイオ後続品)の世界市場動向
・バイオシミラー(バイオ後続品)の世界市場規模
・バイオシミラー(バイオ後続品)の世界市場:業界構造分析
・バイオシミラー(バイオ後続品)の世界市場:用途別(腫瘍学・血液学、内分泌学、免疫学、腎臓学)
・バイオシミラー(バイオ後続品)の世界市場:地域別市場規模・分析
・バイオシミラー(バイオ後続品)の北米市場規模・予測
・バイオシミラー(バイオ後続品)のヨーロッパ・中東・アフリカ市場規模・予測
・バイオシミラー(バイオ後続品)のアジア太平洋市場規模・予測
・バイオシミラー(バイオ後続品)の主要国分析
・バイオシミラー(バイオ後続品)の世界市場:意思決定フレームワーク
・バイオシミラー(バイオ後続品)の世界市場:成長要因、課題
・バイオシミラー(バイオ後続品)の世界市場:競争環境
・バイオシミラー(バイオ後続品)の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Amgen、Biogen、Merck、Novartis、and Pfizerなどです。
【レポートの概要】

About this market
Patients and physician’s willingness to switch to biosimilars is expected to drive growth in the market. Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars. Technavio’s analysts have predicted that the biosimilars market will register a CAGR of almost 35% by 2022.
Market Overview
Price advantage of biosimilars over biologics
High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.
Market access barriers for biosimilars
To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.
For the detailed list of factors that will drive and challenge the growth of the biosimilars market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the patients and physician’s willingness to switch to biosimilars and the price advantage of biosimilars over biologics, will provide considerable growth opportunities to biosimilars manufactures. Amgen, Biogen, Merck, Novartis, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Oncology and hematology – Market size and forecast 2017-2022
• Endocrinology – Market size and forecast 2017-2022
• Immunology – Market size and forecast 2017-2022
• Nephrology – Market size and forecast 2017-2022
• Market opportunity by application
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Patients and physician’s willingness to switch to biosimilars
• Therapeutic interchangeability regulations for biosimilars across countries
• Biosimilar “patent dance”
• Many originator companies entering the biosimilar market
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Biogen
• Merck
• Novartis
• Pfizer
PART 16: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Biosimilars approved by US FDA in 2017 and 2018
Exhibit 06: Biosimilars approved by EMA in 2017 and 2018
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Global – Year-over-year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition – Five forces 2017
Exhibit 20: Application – Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Oncology and hematology – Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Oncology and hematology – Year-over-year growth 2018-2022 (%)
Exhibit 24: Endocrinology – Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Endocrinology – Year-over-year growth 2018-2022 (%)
Exhibit 26: Immunology – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Immunology – Year-over-year growth 2018-2022 (%)
Exhibit 28: Nephrology – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Nephrology – Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by application
Exhibit 31: Customer landscape
Exhibit 32: Global – Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 35: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 41: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in Americas
Exhibit 43: Market opportunity
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amgen – Overview
Exhibit 49: Amgen – Business segments
Exhibit 50: Amgen – Organizational developments
Exhibit 51: Amgen – Geographic focus
Exhibit 52: Amgen – Key offerings
Exhibit 53: Biogen – Overview
Exhibit 54: Biogen – Business segments
Exhibit 55: Biogen – Organizational developments
Exhibit 56: Biogen – Geographic focus
Exhibit 57: Biogen – Key offerings
Exhibit 58: Merck – Overview
Exhibit 59: Merck – Business segments
Exhibit 60: Merck – Organizational developments
Exhibit 61: Merck – Geographic focus
Exhibit 62: Merck – Segment focus
Exhibit 63: Merck – Key offerings
Exhibit 64: Novartis – Overview
Exhibit 65: Novartis – Business segments
Exhibit 66: Novartis – Organizational developments
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Segment focus
Exhibit 69: Novartis – Key offerings
Exhibit 70: Pfizer – Overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings



【掲載企業】

Amgen、Biogen、Merck、Novartis、and Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[バイオシミラー(バイオ後続品)の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆